T Cells as Treatment Targets in Systemic Lupus Erythematosus
Christine Konya and Vasileios C Kyttaris*
Beth Israel Deaconess Medical Center, Division of Rheumatology and Harvard Medical School, USA
- *Corresponding Author:
- Vasileios C Kyttaris
Division of Rheumatology and Harvard Medical School
330 Brookline Ave, CLS-936, Boston MA 02215, USA
E-mail: [email protected]
Received date: March 04, 2013; Accepted date: June 28, 2013; Published date: July 11, 2013
Citation: Konya C, Kyttaris VC (2013) T Cells as Treatment Targets in Systemic Lupus Erythematosus. Rheumatol Curr Res 3:120. doi: 10.4172/2161-1149.1000120
Copyright: © 2013 Konya C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
T cells play a central role in Systemic Lupus Erythematosus (SLE) pathogenesis. The discovery of key steps that lead to SLE T cell dysfunction allowed several investigators to propose targeted treatments for SLE. Herein, we discuss the potential of novel drugs targeting SLE T cells, such as fostamatinib and anti-IL-17 antibodies. Furthermore, we discuss the use of already approved medications such as rapamycin, dipyridamole and N acetylcysteine as targeted therapies for SLE.